Trial Profile
An Intra-patient Placebo-controlled, Phase I Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 (Heat-killed Mycobacterium Obuense) in Adult Melanoma Cancer Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Dec 2019
Price :
$35
*
At a glance
- Drugs IMM 101 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; First in man
- Sponsors Immodulon Therapeutics
- 21 Nov 2019 According to an Immodulon Therapeutics media release, positive results from this phase 1 follow up study supports current phase 2 clinical trial(NCT03711188) of IMM-101 in combination with checkpoint inhibitor therapy.
- 21 Nov 2019 According to an Immodulon Therapeutics media release, Dr Alberto Fusi is the principle investigator of the study.
- 21 Nov 2019 Results published in the Immodulon Therapeutics Media Release.